We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Blood-Based Molecular Test Improves Early Detection of Colorectal Cancer

By LabMedica International staff writers
Posted on 03 Mar 2015
Print article
Image: The Colox test kit for the detection of colorectal cancer (Photo courtesy of Diagnoplex SA).
Image: The Colox test kit for the detection of colorectal cancer (Photo courtesy of Diagnoplex SA).
A convenient blood test can be ordered by a physician during a routine medical checkup to accurately and reliably detect both adenomatous polyps and early stages of colorectal cancer.

Mononuclear cells (PBMCs) are particularly responsive to growing adenomatous polyps and colorectal carcinomas and determining the expression of 29 genes in PBMCs provides a telltale sign of the early stages of colorectal cancer.

The new molecular blood test for the detection of colorectal cancer and precancerous lesions such as adenomatous polyps is called Colox; it has been approved for sale in Europe, and has been launched commercially in Switzerland. Colox is available as a Laboratory Developed Test and is highly suited to standard medical laboratory workflow and is also available as a Conformité Européenne (CE) registered kit.

The Colox test was originally developed by Diagnoplex SA (Epalinges, Switzerland) and represents a new generation of cancer diagnostic tests based on the response of the organism against the tumor. The molecular diagnostics company Novigenix SA (Epalinges, Switzerland) announced it has acquired Colox. Gene expression data are interpreted by Novigenix's proprietary algorithm which generates the Colox test report. This algorithm is based on classifier combinations derived from mathematical analytical methods that underpin the reliability of the test.

Colox has been tested in a multicenter clinical study at the Centre Hospitalier Universitaire Vaudois (Lausanne, Switzerland). Gian Dorta, MD, a professor who led the study said, “Colox accurately and reliably detects both adenomatous polyps and early stages of colorectal cancer with a convenient blood test that can be ordered as part of a routine medical checkup. As a result Colox has the potential to dramatically increase screening compliance and reduce the mortality rate from this deadly disease.”

Brian B Hashemi, PhD MBA, Executive Chairman of Novigenix, said, “Our vision is to support physicians and the healthcare community in significantly reducing cancer mortality through the early diagnosis and intervention of colorectal cancer. We are committed to making Colox available to physicians and patients across Switzerland, followed by expansion in other European countries. Colorectal cancer is today the third most lethal cancer, but can be largely prevented if detected early by an accurate, reliable, and convenient test such as Colox.”

Related Links:
Diagnoplex SA 
Novigenix SA
Centre Hospitalier Universitaire 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.